Life Sciences IP Review

Exciting news! Nominations are now open for the Life Sciences Patent Network (LSPN) Awards USA 2025! Join us in celebrating excellence in life sciences IP—recognizing trailblazing individuals, groundbreaking firms, and the unsung heroes driving progress in this vital industry. Key details: • Awards Gala Dinner: Tuesday, May 6, 2025, following the first day of LSPN North America–Spring 2025 in Boston. • Nomination deadline: Midnight (EST), Friday, January 31, 2025. Award categories include: • Life Sciences IP Firm of the Year • IP Boutique of the Year • Rising Star of the Year • In-House Team of the Year • Lifetime Achievement • And many more! Whether you’re securing critical patents, making an impact behind the scenes, or leading innovation, this is your chance to shine. Submit your nominations today: https://ow.ly/Qqvu50UugQm We can’t wait to see you in Boston!

Would you mind doing us a quick favour? Could you take a few moments to complete our Life Sciences Patent Network (LSPN) Survey 2025? As a leader in life sciences IP, your insights are vital to understanding the challenges and innovations shaping our industry. This is your chance to share your perspective on key issues like groundbreaking technologies, evolving regulations, and the dynamics of a global market: https://lnkd.in/emcjYdVh

You won’t get another chance to hear from so many industry leaders as they tackle the critical challenges shaping life sciences innovation and IP! The past 12 months have seen a series of regulatory developments that could significantly alter patent protection in the life sciences industries in the US. Buckle up for another unparalleled journey through this ever-evolving landscape at the highly anticipated LSPN North America–Spring 2025 conference next year! Back for our 7th year in Boston, the theme for this year is Redefining Boundaries: IP Strategy in a Transformative Era. Protecting and leveraging IP across the innovation lifecycle is at the heart of this year’s event. Explore a world of groundbreaking discoveries, thought-provoking discussions, and invaluable networking opportunities. View the agenda now and start planning your conference experience: https://lnkd.in/eBgicYXi

2024’s most-read news stories: Astellas defends blockbuster cancer patent. The company's life-extending prostate cancer treatment Xtandi survived a UK attack from Accord Healthcare, Sandoz, and Teva. Learn more: https://ow.ly/n2ph50UwqbU

2024’s most-read news stories: BlueAllele–Rival gained $100m from patented tech. The Minnesota biotech firm said Intellia used its patented gene editing innovations and earned more than $100 million from a Regeneron deal. Read the full article here: https://ow.ly/H7TY50Uwqa4

2024’s most-read news stories: Bayer granted 10-day injunction in Teva feud. The pharma company said the ‘window should be shut’ on copycat versions of a blood clot drug for longer due to the potential for irreparable harm. Learn more: https://ow.ly/9zAg50Uwq7p

2024’s most-read news stories: Dexcom has lost another round in its dispute with Abbott, as part of the global litigation series between the companies over glucose monitoring systems. Read the full article here: https://ow.ly/Mz6E50Uwq6i

Regeneron inks deal over suit concerning a protein for testing COVID-19 treatments | BioNTech aims to resolve university dispute over patented tech used in the Comirnaty vaccine. Learn more here: https://ow.ly/Org050Uto3z

LSIPR’s key event series to host its inaugural ceremony next year in Boston | Spotlight on top innovators and firms in life sciences IP | Gala to honour contributions across 21 categories with 15 judges. Learn more here: https://lnkd.in/eX7DXJSK

A Delaware jury unanimously sided with Sanofi-owned biotech Inhibrx, clearing it of trade secrets misappropriation claims. Amy Candido of Wilson Sonsini shares insights into the defence strategy that led to the win. Read more here: https://ow.ly/lEXY50UtnQh